Business Wire

BIAL Launches New Support Platform to Inspire People With Parkinson’s Disease to Stay Active

9.4.2021 15:31:00 EEST | Business Wire | Press release

Share

NOT FOR UK MEDIA DISTRIBUTION

BIAL has developed a new resource centre on its Keep It ON website for World Parkinson’s Day 2021 to empower people living with Parkinson’s disease to stay healthy and active and to help them manage their condition.

Working in partnership with the European Parkinson's Disease Association (EPDA) as well as experts in nutrition, voice and cognition, BIAL plans to create a wealth of resources covering four key areas:

  1. Nutrition: Nutritionist Diana Miranda explains in her videos the importance of keeping hydrated and gives tips on managing common symptoms in Parkinson’s disease such as constipation. The page also features videos from chef Fábio Bernardino discussing recommended recipes for people with the condition.
  2. Exercise: Videos of physiotherapist Josefa Domingos from the EPDA demonstrate challenging and engaging exercises for people with Parkinson’s disease to do at home.
  3. Voice: Voice exercises by Speech Therapist Rita Cardoso are included to help improve communication skills as it is vital people with the condition continue to maintain their social roles and be fully integrated in society.
  4. Cognition: People with Parkinson’s disease can strengthen their cognitive skills and keep their mind active with helpful mental exercises and games by Isabel Araújo.

Although there is plenty of information available online about eating well and staying active, people with Parkinson’s disease have very specific needs when it comes to nutrition and exercise and the content has been designed with these in mind.

Josefa Domingos and John Dean, EPDA Board members and physiotherapist, comments: “We believe in exercising differently. By combining movement, voice and cognition, you can better replicate and consequently improve daily function and activities in Parkinson’s.”

Rui Sobral, Head of BIAL’s Global Parkinson’s Department, comments: “The new training area we have created supports our ongoing commitment to improve the lives of people with Parkinson’s disease around the world. Working with expert partners is critical to ensuring the resources we create can really make a difference to people with Parkinson’s, helping them to eat well, keep moving and stay active every day.”

More information about the new training area featuring tutorials, videos, tips, recipes and games is available at bial-keepiton.com/training-area/. The training area will continue to be updated after World Parkinson’s Day with new content.

Since 2017, BIAL has developed global campaigns associated with World Parkinson's Day to increase awareness of the disease and how it affects people directly and indirectly. The films which have been created as part of the campaigns have had more than 1.2 million views to date, and aim to depict how some of the limitations associated with the disease can be overcome with the understanding and support of all. Films include:

- 2020: Keep on moving

- 2019: Speak up for Parkinson's

- 2018: There's no right rhythm for life

- 2017: Me at my best

__________________________________________________________________

About BIAL
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide. For more information on BIAL: www.bial.com

About Parkinson’s Disease
Parkinson's disease is a chronic, progressive neurodegenerative disorder characterised by a strong reduction of the neurotransmitter dopamine, caused by the degeneration of certain neurons in the brain. Epidemiological evidence highlights a complex interaction between genetic vulnerability and environmental factors. The clinical manifestations usually appear after the age of 50 years (the average age of diagnosis is approximately 60 years). The prevalence of the disease is estimated at 300 per 100,000 inhabitants, increasing to 1 in 100 in the age group between 55 and 60 years. The European Parkinson's Disease Association (EPDA) estimates that approx. 1.2 million people suffer from this disease in Europe. The diagnosis of Parkinson's disease is based on clinical observation and relies on three key elements: bradykinesia (slow movements), resting tremor, and rigidity (muscle stiffness). Of these, bradykinesia must be present, with at least either tremor or rigidity. Other common symptoms are postural instability, reduced facial expression and blinking, and a slouching posture. The disease progressively incapacitates patients, causing hindrance in their lives and daily activities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries
Susana Vasconcelos
T. +351 229 866 100 | E. susana.vasconcelos@bial.com

Gurjit Chahal
T: +44 (0) 7917 796 836 | E. gurjit@makarahealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

European Commission Approves Crysvita ® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union21.7.2026 10:00:00 EEST | Press release

Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area. The approval represents an important step forward for infants living with XLH, a rare, progressive genetic disease that can affect skeletal development from an early age. Earlier diagnosis and treatment are considered important in XLH given the potential impact of the disease on skeletal development during infancy and childhood. XLH is a rare, progressive, lifelong genetic disease characterised by phosphate wasting that can impair bone mineralisation from an early age, leading to skeletal deformities, impaired growth and other serious complications. Clinical manifestations of XLH can emerge during infancy and early childhood, with pr

CapVest Completes Acquisition of TSG21.7.2026 10:00:00 EEST | Press release

CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, today announces that it has completed its acquisition of a majority stake in TSG Solutions (“TSG”), a European leader in technical services for critical energy infrastructure, following receipt of all necessary approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721628079/en/ TSG Headquartered in Paris, France, TSG operates across 30 countries with over 7,000 employees and annual revenues of more than €1.4 billion. The company designs, builds and maintains critical energy infrastructure across Power (HV, MV & LV electrical), Charge, Solar, Battery Energy Storage Systems (BESS), Biofuels and Gas & Biogas. TSG’s multi-energy capabilities, deep technical expertise and extensive geographical coverage underpin longstanding relationships with a diverse base of leading energy infrastructure operators, and position the company to capture

Ant International Raises approx. US$1.2 billion in Series A Equity Financing to Boost Cross-border Payments, Agentic Commerce Solutions for Global Businesses21.7.2026 06:00:00 EEST | Press release

Ant International, a leading global digital payment, digitisation and financial technology provider, today announced the successful closing of its Series A equity financing of approximately US$1.2 billion. Existing investors including Ant Group and Alibaba Group participated in this round, as well as other renowned international investment institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720424592/en/ Ant International today announced the successful closing of its Series A equity financing of approximately US$1.2 billion. The proceeds will be used to accelerate Ant International’s global expansion and innovation in merchant payment, account management and other inclusive financial services for SMEs and enterprises across the world. Ant International began independent operation in 2024. With main operations across Asia, Europe, the Middle East and Latin America, the company has built an expansive partnership ne

Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension20.7.2026 23:00:00 EEST | Press release

Brenus Pharma today announced an €11 million ($12.6M) extension to its Series A round, bringing total capital raised since inception to €38 million ($43.5M). This funding reflects strong execution across clinical, regulatory, and business development milestones, de-risking STC-1010 (NCT06934538): lead clinical-stage in-vivo immunotherapy for MSS mCRC, while positioning the company’s proprietary platform for multi-asset expansion. The round was supported by strong follow-on participation from existing investors, including Angelor, UI Investissement (managing FRAI), Crédit Agricole (CACE Création, CACF Capital Innovation), Noshaq, Orsa (formerly Investsud), BIO JAG, and Bpifrance (through non-dilutive funding). This round also welcomes two new international investors: Sambrinvest, strengthening the company’s European shareholder base, and Korea Omega Investment Corp, marking its first institutional investment from the Asia-Pacific region. "We couldn't be more confident in our first inves

Hollywood Chamber of Commerce Expands Into Luxury Hospitality20.7.2026 19:30:00 EEST | Press release

The Hollywood Chamber of Commerce, known for the iconic Hollywood Sign® and Hollywood Walk of Fame®, is expanding into luxury hospitality through a strategic partnership with The Scene Hotels & Resorts to launch Hollywood Hotels & Residences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720026178/en/ The Scene Hotels & Resorts, with 40+ years of combined expertise in hospitality, travel, and brand development, will lead the brand’s development and management. The partnership will bring the Hollywood lifestyle to luxury hotels and branded residences around the world, creating immersive destinations inspired by the world's entertainment capital. "This partnership represents far more than an expansion of the Hollywood brand—it reflects our vision of Hollywood as the world's premier hub for entertainment, creativity, and commerce," said Ron Frierson, President & CEO of the Hollywood Chamber of Commerce. "By deepening our in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye